The Goal Was Never to Manage Your Pain Forever | The Pained Brain, Chapter 15

Corticosteroid-induced hyperglycemia

Corticosteroid-Induced Hyperglycemia After Joint Injections

Corticosteroid-induced hyperglycemia after a joint injection is measurable: in patients with type 2 diabetes, one immediate-release triamcinolone knee injection produced a median maximum-glucose rise of 169.1 mg/dL over days 1 to 3, and 93 percent exceeded 250 mg/dL. A review of 7 studies found a rise in every study and advised monitoring for up to a week.

Most injection referrals document the joint and leave out the patient’s metabolism. The evidence on systemic steroid effects and regenerative outcomes argues for measuring glucose control, body composition and fall risk before the next procedure is scheduled.

Corticosteroid-induced hyperglycemia after a joint or epidural injection rarely appears in the referring chart, yet the literature now describes systemic effects that primary care owns: glycemic excursions, adrenal suppression and fracture. The same metabolic variables predict which patients fail a regenerative injection. The chapter video, The Goal Was Never to Manage Your Pain Forever, presents chapter 15 of The Pained Brain by Dr. Gurpreet Singh Padda, MD, MBA, MHP, and Dr. KrisJay Fucanan, MD. Trial-level detail, with the limits of each study, is in the book companion for chapter 15.

What does a steroid injection do to blood sugar, adrenal function and bone?

Three signals deserve a place in the referring chart. In patients with type 2 diabetes and an A1c of 6.5 to 9.0 percent, continuous glucose monitoring after one immediate-release triamcinolone knee injection showed a median maximum-glucose rise of 169.1 mg/dL over days 1 to 3; 93 percent exceeded 250 mg/dL, and time in range fell to 48 percent against 62 percent with the extended-release formulation. That was a post hoc analysis of thirty-three patients, but a systematic review of 7 studies and 72 patients found a rise in every study and advised monitoring for up to a week.

A double-blind comparison of epidural triamcinolone found hypothalamic-pituitary-adrenal suppression lasting 19.7 days at 40 mg against 8.0 days at 20 mg, with no difference in analgesia. And among 25,062 Medicare patients given epidural steroid for radiculopathy, mean age 76 and 74 percent female, fractures at typical osteoporotic sites ran 49.1 per 1,000 person-years against 35.2 in unexposed patients, a hazard of 1.39 overall and 1.54 at the vertebrae, with higher early risk after three or more injections in a year.

Why do the side effects of repeat steroid injections go untracked?

Two biological drivers concentrate the risk. Insulin resistance determines how far glucose travels after a steroid load, and adiposity raises both the mechanical demand on the joint and the likelihood that the injection will be repeated. The third driver is structural. Each injection is documented as a discrete procedure, relief arrives quickly, and nobody owns the cumulative record across episodes. Of osteoarthritis patients in British primary care, 10.8 percent had a steroid injection, and 40 percent of that group had repeat injections. The rheumatology guideline that strongly recommends the injection sets no numeric cap on frequency, so the running total is tracked only if the referring physician tracks it.

Dr. Padda has said plainly that he spent years reassuring patients whose A1c sat in the prediabetic band. That reassurance does not survive the regenerative outcome data, and it has no place in a referral note.

Does diabetes make PRP less likely to work?

Where platelet-rich plasma is under consideration, the metabolic workup becomes prognostic. In a retrospective case-control study of 120 patients with Achilles or patellar tendinopathy, 60 of them with diabetes or prediabetes, the odds of failing to reach the minimal important difference were 2.41, and 2.54 for a 20-point improvement. Glycated hemoglobin independently predicted a poor outcome at an odds ratio of 1.16, and body mass index at 1.02. In knee cohorts, body mass index and radiographic grade were the independent predictors of failure, which reached 15.3 percent at a mean of nearly five years.

Growth-factor content in the preparation did not differ between lean and obese patients. Inflammatory content did track body mass: interleukin-18 rose with body mass index and predicted weaker functional gains in a small single-injection series. The preparation is not the main variable. The recipient is, and the recipient can be measured before the procedure is scheduled.

Who should have blood sugar checked before a steroid injection?

Metabolic health is the exception rather than the default in adults: under 12.2% of US adults qualified on NHANES 2009–2016, and under 7% on the tighter criteria applied after 2021. Reasonable candidates include:

Patients with known diabetes or an A1c in the prediabetic range, before any corticosteroid injection, so glucose monitoring for the following week can be planned in advance.
Patients with obesity, where body mass index conflates fat mass with lean mass.
Older adults receiving epidural steroid, particularly those approaching three or more injections in a year, where fracture exposure and fall risk belong in one plan.
Patients referred for a regenerative injection, where A1c and body composition inform the expected response.
Patients within three months of planned knee arthroplasty. Across 58,337 primary knee replacements, corticosteroid injection in that window carried an infection odds ratio of 1.21 on a 2.74 percent base rate, and hyaluronic acid 1.55, a timing signal the surgeon and the referring physician should share.

What Measura measures, and what it does not

Measura [Cardiometabolic and Autonomic Health Analysis] is a testing service. It performs no injections, no imaging and no treatment, and results return to the ordering physician. Three measurements apply to this pathway: laboratory panels for the glycemic and lipid picture; bioimpedance body composition for fat and lean compartments; and vestibular and balance testing for older patients whose fracture exposure after epidural steroid makes fall risk a management question. None of these measures bone density, and a balance result does not substitute for one. Pairing balance findings with a cognitive baseline follows the cognitive assessment and fall prevention workflow.

Standing orders, the referral letter and documentation

A standing order that attaches a laboratory panel including A1c and a body composition measurement to referrals for joint or epidural injection takes the decision out of the individual encounter, which is the only way the cumulative record gets built. Results filed as discrete data in the record remain visible when the procedure note returns. The referral letter can ask that the note record the agent, formulation and dose, since the glycemic and adrenal effects scale with them. One Medicare contractor policy already allows no more than four epidural steroid sessions in a spinal region over a rolling year and rejects a predetermined series as not medically reasonable. Cardiometabolic findings also support documentation that MIPS and quality reporting asks practices to capture, as documentation rather than a reason to test.

What the evidence does not settle

The cohort harm signals carry confounding by indication. When steroid was compared against hyaluronic acid, which ensured both arms had knees judged worth injecting, joint-space narrowing progressed at a rate ratio of 1.00. The fracture data are claims-based in a population that may be frailer at baseline, and the tendinopathy outcome data are retrospective. Exercise remains the comparator an injection has to beat: in a randomized trial of 273 patients, a year of exercise-based physical therapy outperformed a glucocorticoid injection by 22.70 WOMAC points. The practice position is that the injection is a bridge and the metabolic work is the destination, which makes measuring the terrain the referring physician’s share of the plan. The patient-facing version is what a cortisone shot does to blood sugar.

Frequently asked questions

Should patients with diabetes monitor glucose after a corticosteroid joint injection?

The data support it. After one immediate-release triamcinolone knee injection, patients with type 2 diabetes had a median maximum-glucose rise of 169.1 mg/dL, and median time to 250 mg/dL was 6 hours. A review of 7 studies advised monitoring for up to a week. Any change to diabetes therapy remains the treating physician’s decision. Interpreting the report covers how Measura results reach the ordering physician.

Does A1c predict response to platelet-rich plasma?

In one retrospective study of 120 tendinopathy patients, each unit of glycated hemoglobin raised the odds of a poor outcome 1.16-fold, and diabetes or prediabetes more than doubled the odds of missing a meaningful improvement. Growth-factor content did not differ by body mass, which points to the recipient tissue rather than the preparation. Prospective confirmation is still lacking. The clinical rationale for measuring first follows the same logic.

Is epidural steroid associated with fracture in older adults?

In 25,062 Medicare patients with radiculopathy, epidural steroid was associated with osteoporotic-site fractures at 49.1 per 1,000 person-years against 35.2, with a vertebral hazard of 1.54. Claims data cannot exclude frailer patients being selected for injection, and a small low-dose cohort found no bone density change. Fall risk still belongs in the plan. Practice-level selection criteria summarize who to test.

Where does metabolic testing fit in the annual wellness visit?

That visit already records fall risk and cognitive status, which makes it the natural place to attach laboratory and body composition measurement for a patient with chronic joint or spine pain. Doing it there means the baseline exists before the first injection referral rather than being reconstructed after the third. Annual wellness visit integration describes the workflow.

Does Measura perform or recommend injections?

No. Measura measures metabolic, body composition, vascular, autonomic, nerve, balance and cognitive function and reports to the ordering physician. Injection decisions, dosing and timing stay with the treating clinicians. The testing supplies the context a procedure note lacks, and what changes for the patient describes how findings are used.

How long does blood sugar stay high after a steroid injection?

The rise starts within hours and can last most of a week. In patients with type 2 diabetes given one immediate-release triamcinolone knee injection, median time to reach 250 mg/dL was 6 hours, and the largest rise came over days 1 to 3. A review of 7 studies found a rise in every study and advised monitoring glucose for up to a week after the shot.

Is a cortisone shot bad for people with diabetes?

It pushes glucose well out of range for most of them. After one immediate-release triamcinolone knee injection, 93 percent of patients with type 2 diabetes exceeded 250 mg/dL, and time in range fell to 48 percent, against 62 percent with the extended-release formulation. That is a reason to plan a week of glucose monitoring before the injection, not after it. Any change to diabetes medicine stays with the treating physician.

How many steroid injections can you get in a year?

The rheumatology guideline that recommends joint injections sets no numeric cap, so the running total is tracked only if someone tracks it. One Medicare contractor policy allows no more than four epidural steroid sessions in a spinal region over a rolling year. In older Medicare patients, fracture risk ran higher early on after three or more epidural injections in a year.

Attach measurement to the injection pathway

See how the Measura protocol adds metabolic, body composition and balance testing to injection referrals, with results returned to the ordering physician.

Send a message

4477 Woodson Rd, Suite 201, St. Louis, MO 63134. Monday to Friday, 9:00 a.m. to 5:00 p.m. Please do not send symptoms, diagnoses or images through a web form — a website form is not a secure medical channel. Send your name and number and we will call you back.

References

Spitzer, A. I., Rodbard, H. W., Iqbal, S. U., Nakazawa, M., DiGiorgi, M., & Winston, R. (2024). Extended-Release Versus Immediate-Release Triamcinolone Acetonide in Patients Who Have Knee Osteoarthritis and Type 2 Diabetes Mellitus. The Journal of Arthroplasty, 39(9 Suppl 2), S218-S223.e1. https://doi.org/10.1016/j.arth.2024.05.055
Choudhry, M. N., Malik, R. A., & Charalambous, C. P. (2016). Blood Glucose Levels Following Intra-Articular Steroid Injections in Patients with Diabetes: A Systematic Review. JBJS Reviews, 4(3), e5. https://doi.org/10.2106/JBJS.RVW.O.00029
Sim, S. E., Hong, H. J., Roh, K., Seo, J., & Moon, H. S. (2020). Relationship Between Epidural Steroid Dose and Suppression of Hypothalamus-Pituitary-Adrenal Axis. Pain Physician, 23(4S), S283-S294. https://pubmed.ncbi.nlm.nih.gov/32942788/
Yun, H., Liu, Y., Curtis, J. R., Saag, K., D’Erasmo, G., Haseltine, K., & Stein, E. M. (2025). Epidural steroid injections and fracture incidence among older individuals with radiculopathy. Journal of Bone and Mineral Research, 40(2), 176–183. https://doi.org/10.1093/jbmr/zjae162
Whitehouse, M. R., Judge, A., Hawley, S., Prats Uribe, A., Delmestri, A., Matharu, G., Moore, A., Palmer, C., Wylde, V., Anderson, E., Donovan, R., Jameson, C., Snelling, N., Blom, A. W., Gooberman-Hill, R., Barker, K., & Prieto-Alhambra, D. (2025). RecUrrent Intra-articular Corticosteroid injections in Osteoarthritis: the RUbICOn mixed-methods study. Health Technology Assessment, 29(56), 1-167. https://doi.org/10.3310/LFAJ9337
Abate, M., Paganelli, R., Pellegrino, R., Di Iorio, A., & Salini, V. (2024). Platelet Rich Plasma Therapy in Achilles and Patellar Tendinopathies: Outcomes in Subjects with Diabetes (A Retrospective Case-Control Study). Journal of Clinical Medicine, 13(18), 5443 (article number from DOI; PubMed record lists volume 13, issue 18). https://doi.org/10.3390/jcm13185443
Alessio-Mazzola, M., Lovisolo, S., Sonzogni, B., Capello, A. G., Repetto, I., Formica, M., & Felli, L. (2021). Clinical outcome and risk factor predictive for failure of autologous PRP injections for low-to-moderate knee osteoarthritis. Journal of Orthopaedic Surgery (Hong Kong), 29(2), 23094990211021922. https://doi.org/10.1177/23094990211021922
Wiciński, M., Szwedowski, D., Wróbel, Ł., Jeka, S., & Zabrzyński, J. (2022). The Influence of Body Mass Index on Growth Factor Composition in the Platelet-Rich Plasma in Patients with Knee Osteoarthritis. International Journal of Environmental Research and Public Health, 20(1), 40 (article number from DOI; PubMed record lists volume 20, issue 1). https://doi.org/10.3390/ijerph20010040
Richardson, S. S., Schairer, W. W., Sculco, T. P., & Sculco, P. K. (2019). Comparison of Infection Risk with Corticosteroid or Hyaluronic Acid Injection Prior to Total Knee Arthroplasty. The Journal of Bone and Joint Surgery. American Volume, 101(2), 112-118. https://doi.org/10.2106/JBJS.18.00454
Lee, M., Jing, C., & Lee, K. (2025). Physical therapy vs. glucocorticoid injection in patients with meniscal tears and knee osteoarthritis: a multi-center, randomized, controlled trial. BMC Medicine, 23(1), 277. https://doi.org/10.1186/s12916-025-04113-y